New cocktail of drugs takes on tough pancreatic cancer

NCT ID NCT07445295

Not yet recruiting Disease control Sponsor: Chipscreen Biosciences, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase III trial is testing whether adding the experimental drug chiauranib and an immunotherapy (toripalimab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 558 participants will be randomly assigned to receive either the full combo or chemo plus placebos. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chiauranib, toripalimab, albumin-paclitaxel, gemcitabine
What this could lead to: If successful, this combination could become a new first-line treatment option for metastatic pancreatic cancer, potentially improving survival and disease control.
What could go wrong: This is an early-stage Phase III trial with no results yet. The added drugs may increase side effects without improving outcomes, and pancreatic cancer is notoriously hard to treat.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.